comparemela.com

Lipoprotein A News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Oral Muvalaplin effectively lowers lipoprotein (a) with no serious adverse effects, shows Initial phase 1 trial

Australia: Daily administration of Muvalaplin, a selective small molecule inhibitor of Lp(a) formation, for 14 days lowered Lipoprotein(a) levels up to 65% and was not associated with tolerability.

Lipoprotein(a) levels tied to onset of aortic valve calcification, not progression: Study

Netherlands: Lipoprotein(a) is robustly associated with the development of aortic valve calcification (AVC) but not with the progression of calcification over long-term follow-up, says a recent study..

Increase in Lipoprotein (a) levels during COVID-19 hospitalization tied to VTE risk: Study

Netherlands: Results from a pilot study published in the journal Atherosclerosis showed that in patients hospitalized with COVID-19, the levels of lipoprotein(a) increase threefold during.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.